There are 2137 resources available
1912TiP - NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery
Presenter: Rajiv Shah
Session: E-Poster Display
Resources:
Abstract
1915P - The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial
Presenter: Christine Dierks
Session: E-Poster Display
Resources:
Abstract
1916P - Larotrectinib treatment of advanced TRK fusion thyroid cancer
Presenter: Maria E. Cabanillas
Session: E-Poster Display
Resources:
Abstract
1917P - Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial
Presenter: Bryan Haugen
Session: E-Poster Display
Resources:
Abstract
1918P - Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC)
Presenter: Marcia S. Brose
Session: E-Poster Display
Resources:
Abstract
1919P - Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study (NCT01788982)
Presenter: Kate Newbold
Session: E-Poster Display
Resources:
Abstract
1920P - Anlotinib in medullary thyroid carcinoma: A subanalysis based on ALTER01031 study for patients with high prognostic risk
Presenter: Ming Gao
Session: E-Poster Display
Resources:
Abstract
1921P - Prognostic impact of [18F]FDG-PET/CT in differentiated thyroid cancer with bone metastasis: A French TUTHYREF study
Presenter: Arnaud Jannin
Session: E-Poster Display
Resources:
Abstract
1922P - Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292)
Presenter: Lori Wirth
Session: E-Poster Display
Resources:
Abstract
1923P - Assessment of the efficacy and safety of lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer in real-life practice in Russia
Presenter: Ekaterina Borodavina
Session: E-Poster Display
Resources:
Abstract